Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Toxicology and Applied Pharmacology|February 19, 2013
Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of actionYusheng Qu, Mei Fang, BaoXi Gao, et al.
Journal of Pharmacological and Toxicological Methods|July 28, 2024
Detection of contractility changes in the heart from arterial blood pressure data using symmetric Projection Attractor ReconstructionEsther Bonet-Luz, Manasi Nandi, Mark I Christie, et al.
American Heart Journal|August 25, 2009
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path InitiativeJonathan P Piccini, David J Whellan, Brian R Berridge, et al.
British Journal of Pharmacology|June 3, 2015
Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordanceHugo M Vargas, Alan S Bass, John Koerner, et al.
Journal of Pharmacological and Toxicological Methods|February 23, 2017
Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practiceSimon Authier, Michael K Pugsley, John E Koerner, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 11, 2022
The Challenges of Predicting Drug-Induced QTc Prolongation in HumansJean-Pierre Valentin, Peter Hoffmann, Catherine Ortemann-Renon, et al.
Journal of Pharmacological and Toxicological Methods|April 10, 2013
A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical CommitteeJennifer B Pierson, Brian R Berridge, Marjory B Brooks, et al.
Regulatory Toxicology and Pharmacology : RTP|May 16, 2019
Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraineJeanine L Bussiere, Rhian Davies, Charles Dean, et al.
Regulatory Toxicology and Pharmacology : RTP|May 8, 2016
Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trialsAndy N Mead, Hamid R Amouzadeh, Kathryn Chapman, et al.
Pageof 7